Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EFFECT OF INTRAVENOUS IRON SUPPLEMENTATION ON CELIAC DISEASE REMISSION IN PATIENTS WITH IRON DEFICIENCY AND INTESTINAL VILLOUS ATROPHY: A RANDOMIZED TRIAL

Next Previous
Trial Profile

EFFECT OF INTRAVENOUS IRON SUPPLEMENTATION ON CELIAC DISEASE REMISSION IN PATIENTS WITH IRON DEFICIENCY AND INTESTINAL VILLOUS ATROPHY: A RANDOMIZED TRIAL

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Coeliac disease; Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms IRONCEL

Most Recent Events

  • 17 Jan 2022 Planned End Date changed from 15 Jan 2026 to 15 Apr 2026.
  • 17 Jan 2022 Planned primary completion date changed from 15 Jan 2026 to 15 Apr 2026.
  • 17 Jan 2022 Planned initiation date changed from 15 Nov 2021 to 15 Feb 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top